Company Filing History:
3 out of 417 
2 out of 855 
1 out of 38 
Years Active: 2013-2023
Title: Keisuke Ohsumi: Innovator in Cancer Treatment
Introduction
Keisuke Ohsumi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 4 patents, Ohsumi's work focuses on developing effective methods for treating cancer.
Latest Patents
One of his latest patents is the "NY-ESO-1-containing artificial adjuvant vector cell for use in treatment of cancer." This invention aims to provide clinically applicable aAVC-NY-ESO-1 cells that stably express NY-ESO-1, which can be used in treating patients with NY-ESO-1-expressing cancers. The invention includes a human-derived cell that comprises a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, operably linked to an inducible promoter. Another significant patent is the "Method for treating cancer using artificial adjuvant cell (aAVC)." This invention addresses the need for an effective and safe method for treating or preventing cancer using aAVC. It identifies suitable ranges for the dose of α-GalCer loaded on aAVC cell surfaces, ensuring effectiveness and safety in cancer treatment.
Career Highlights
Ohsumi has worked with notable companies such as Astellas Pharma GmbH and RIKEN Corporation. His experience in these organizations has contributed to his expertise in the field of cancer research and treatment.
Collaborations
Some of his coworkers include Shinichiro Fujii and Koji Yoshikawa. Their collaboration has likely played a role in advancing Ohsumi's research and innovations.
Conclusion
Keisuke Ohsumi is a dedicated inventor whose work in cancer treatment has the potential to make a significant impact on patient care. His innovative patents reflect his commitment to advancing medical science and improving treatment options for cancer patients.